12:55 AM EDT, 07/16/2026 (MT Newswires) -- Medincell (MEDCL.PA) obtained non-dilutive loans totaling 28 million euros amid a plan to repay half of a 40 million-euro credit facility with the European Investment Bank. The biopharmaceutical company said Wednesday it secured the five-year loans without covenants or equity-linked instruments from four commercial banks in Europe. The company plans to repay 20 million euros of its outstanding credit facility, maturing in December 2027, by the end of July 2026. It intends to settle the remaining half of the credit facility by July 2028. Medincell expects the transactions to extend its overall debt maturity to July 2031.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.